Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome.

Schipper LG, van Hulst LT, Grol R, van Riel PL, Hulscher ME, Fransen J.

Rheumatology (Oxford). 2010 Nov;49(11):2154-64. doi: 10.1093/rheumatology/keq195. Epub 2010 Jul 29.

PMID:
20671022
2.

Improving the routine management of rheumatoid arthritis: the value of tight control.

Mease PJ.

J Rheumatol. 2010 Aug 1;37(8):1570-8. doi: 10.3899/jrheum.091064. Epub 2010 Jul 1. Review.

5.

Drug management of early rheumatoid arthritis - 2008.

Sokka T, Mäkinen H.

Best Pract Res Clin Rheumatol. 2009 Feb;23(1):93-102. doi: 10.1016/j.berh.2008.08.003. Review.

PMID:
19233049
6.

Assessment and management of rheumatoid arthritis.

Haraoui B.

J Rheumatol Suppl. 2009 Jun;82:2-10. doi: 10.3899/jrheum.090124. Review. Erratum in: J Rheumatol. 2009 Aug;36(8):1851.

PMID:
19509324
7.

Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.

Gaujoux-Viala C, Smolen JS, Landewé R, Dougados M, Kvien TK, Mola EM, Scholte-Voshaar M, van Riel P, Gossec L.

Ann Rheum Dis. 2010 Jun;69(6):1004-9. doi: 10.1136/ard.2009.127225. Epub 2010 May 6. Review.

PMID:
20447954
8.
9.

Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.

Farahani P, Levine M, Gaebel K, Thabane L.

Can J Clin Pharmacol. 2005 Fall;12(3):e254-63. Epub 2005 Nov 7. Review.

PMID:
16278497
10.

Key randomized trials of single agents in early rheumatoid arthritis.

van de Putte LB.

J Rheumatol Suppl. 2002 Nov;66:13-9. Review.

PMID:
12435164
11.

Remission in early rheumatoid arthritis.

Ma MH, Scott IC, Kingsley GH, Scott DL.

J Rheumatol. 2010 Jul;37(7):1444-53. doi: 10.3899/jrheum.091131. Epub 2010 Jun 1. Review.

PMID:
20516031
12.

Long-term outcomes of rheumatoid arthritis.

Sokka T.

Curr Opin Rheumatol. 2009 May;21(3):284-90. doi: 10.1097/BOR.0b013e32832a2f02. Review.

PMID:
19342954
13.

How should rheumatoid arthritis disease activity be measured today and in the future in clinical care?

Sokka T.

Rheum Dis Clin North Am. 2010 May;36(2):243-57. doi: 10.1016/j.rdc.2010.02.007. Review.

PMID:
20510232
14.

Optimizing treatment with biologics.

Mader R, Keystone E.

J Rheumatol Suppl. 2007 Nov;80:16-24. Review.

PMID:
17985419
15.

Therapy of rheumatoid arthritis: new developments and trends.

St Clair EW.

Curr Rheumatol Rep. 1999 Dec;1(2):149-56. Review.

PMID:
11123029
16.

A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.

Choy EH, Smith C, Doré CJ, Scott DL.

Rheumatology (Oxford). 2005 Nov;44(11):1414-21. Epub 2005 Jul 19. Review.

PMID:
16030080
17.

Preventing joint damage as the best measure of biologic drug therapy.

Bresnihan B.

J Rheumatol Suppl. 2002 Sep;65:39-43. Review.

PMID:
12236622
18.

Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.

Zintzaras E, Dahabreh IJ, Giannouli S, Voulgarelis M, Moutsopoulos HM.

Clin Ther. 2008 Nov;30(11):1939-55. doi: 10.1016/j.clinthera.2008.11.007. Review.

PMID:
19108784
19.

Patient-driven outcomes in rheumatoid arthritis.

Wells GA.

J Rheumatol Suppl. 2009 Jun;82:33-8. doi: 10.3899/jrheum.090129. Review.

PMID:
19509328
20.

RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care.

Pincus T, Yazici Y, Bergman MJ.

Rheum Dis Clin North Am. 2009 Nov;35(4):773-8, viii. doi: 10.1016/j.rdc.2009.10.008. Review.

PMID:
19962621

Supplemental Content

Support Center